Results 31 to 40 of about 2,329 (147)

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives

Cells, 2022
Sphingosine-1-phosphate (S1P) and S1P receptors (S1PR) are bioactive lipid molecules that are ubiquitously expressed in the human body and play an important role in the immune system.
Gary Álvarez Bravo, René Robles Cedeño, Marc Puig Casadevall, Lluís Ramió-Torrentà   +3 more
doaj   +1 more source

Cellular Respiration in Thymic Fragments from Mice

Frontiers in Bioscience-Landmark, 2022
Background: This report aims to detail the use of the phosphorescence oxygen analyzer for in vitro investigation of thymic responses to pharmaceutical agents, in particular immunosuppressants and immunomodulators.
Mariam Alshamsi, Maya Hassane, Farida Almarzooqi, Abdul-Kader Souid   +3 more
doaj   +1 more source

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study [PDF]

, 2019
© The Author(s), 2018. Background: Ozanimod, an oral immunomodulator, selectively targets sphingosine 1-phosphate receptors 1 and 5. Objective: Evaluate efficacy, safety, and tolerability of ozanimod in relapsing multiple sclerosis.
Steinman, L., Kappos, L., Cohen, J. A., Selmaj, K. W., Cree, B. A., Skolnick, B. E., Arnold, D. L., +4 additional authors, Bar-Or, A., Havrdová, E. K., Comi, G.   +10 more
core   +3 more sources

Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects

Neurology International, 2020
Multiple sclerosis (MS) is a prevalent and debilitating neurologic condition characterized by widespread neurodegeneration and the formation of focal demyelinating plaques in the central nervous system. Current therapeutic options are complex and attempt
Grace Lassiter, Carlie Melancon, Tyler Rooney, Anne-Marie Murat, Jessica S. Kaye, Adam M. Kaye, Rachel J. Kaye, Elyse M. Cornett, Alan D. Kaye, Rutvij J. Shah, Omar Viswanath, Ivan Urits   +11 more
doaj   +1 more source

Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. Secondary Progressive Multiple Sclerosis: Implications for the Efficacy of Fingolimod

Frontiers in Cellular Neuroscience, 2022
Multiple sclerosis (MS) is an immune-mediated demyelinating disease that alters central nervous system (CNS) functions. Relapsing-remitting MS (RRMS) is the most common form, which can transform into secondary-progressive MS (SPMS) that is associated ...
Yasuyuki Kihara, Yunjiao Zhu, Deepa Jonnalagadda, William Romanow, Carter Palmer, Carter Palmer, Benjamin Siddoway, Richard Rivera, Ranjan Dutta, Bruce D. Trapp, Jerold Chun   +10 more
doaj   +1 more source

Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review

Bioengineering, 2023
Introduction. Cognitive impairment represents one of the most hidden and disabling clinical aspects of multiple sclerosis (MS). In this regard, the major challenges are represented by the need for a comprehensive and standardised cognitive evaluation of ...
Vincenzo Carlomagno, Massimiliano Mirabella, Matteo Lucchini   +2 more
doaj   +1 more source

A REVIEW ON PHARMACOLOGICAL AND THERAPEUTIC INSIGHT OF OZANIMOD FOR COLON DISEASE IN NANO-STRUCTURE [PDF]

, 2022
Current drug treatments are focused on pharmacological and chemotherapeutical treatment such as controlling the acute and chronic aggravation of diseases, maintaining remission, treating specific complications, and reducing the toxic effects.
MAJUMDER, SUBHABROTA, GANGULY, DEBGOPAL, GHOSH, SOUMYADIP   +2 more
core   +1 more source

Impact of S1P Mimetics on Mesenteric Ischemia/Reperfusion Injury

Pharmaceuticals, 2020
Mesenteric ischemia/reperfusion (I/R), following the transient deprivation of blood flow to the gut, triggers an acute flogistic process involving the disruption of endothelial and epithelial barriers integrity, the activation of immune cells, and the ...
Francesco Potì, Carmine Giorgio, Irene Zini, Jerzy-Roch Nofer, Valentina Vivo, Simone Palese, Vigilio Ballabeni, Elisabetta Barocelli, Simona Bertoni   +8 more
doaj   +1 more source

Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia

, 2023
Introduction: Fingolimod is a disease-modifying therapy for multiple sclerosis (MS) that modulates sphingosine 1-phospate receptors, impeding the egress of lymphocytes from lymphnodes and thus causing lymphopenia.
Lanzillo, Roberta, Petracca, Maria, Carotenuto, Antonio, Brescia Morra, Vincenzo, Grassia, Maria Carmela, Moccia, Marcello, Caliendo, Daniele   +6 more
core   +1 more source

P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis

, 2023
Background Ozanimod is approved in the European Union, United States, and other countries for the treatment of moderately to severely active ulcerative colitis in adults (UC).
Danese, S, Canavan, J B, Panaccione, R, Wolf, D C, Wu, H, Jain, A, Afzali, A, Abreu, M T, Petersen, A   +8 more
core   +1 more source